Who are SARS-CoV-2 rS antigen/Matrix-M Adjuvant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CCP, Novavax recombinant protein vaccine, protein subunit: Novavax COVID-19 vaccine, Ad26.COV2.S vaccine, COVAX only (1st and 2nd dose), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sars-cov-2-rs-antigen-matrix-m-adjuvant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SARS-CoV-2 rS antigen/Matrix-M Adjuvant — Competitive Intelligence Brief

SARS-CoV-2 rS antigen/Matrix-M Adjuvant (SARS-CoV-2 rS antigen/Matrix-M Adjuvant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine with adjuvant. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine with adjuvant SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

SARS-CoV-2 rS antigen/Matrix-M Adjuvant (SARS-CoV-2 rS antigen/Matrix-M Adjuvant) — Novavax. This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SARS-CoV-2 rS antigen/Matrix-M Adjuvant TARGET	SARS-CoV-2 rS antigen/Matrix-M Adjuvant	Novavax	phase 3	Recombinant protein vaccine with adjuvant	SARS-CoV-2 spike protein
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine with adjuvant class)

Novavax · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SARS-CoV-2 rS antigen/Matrix-M Adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/sars-cov-2-rs-antigen-matrix-m-adjuvant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab